^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    brenetafusp (IMC-F106C)

    i
    Company:
    Immunocore
    Drug class:
    CD3 agonist, PRAME inhibitor
    Related drugs:
    Apply
    IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (NCT06112314)
    Phase 3
    Immunocore Ltd
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    12/18/2023
    Primary completion :
    12/01/2026
    Completion :
    12/01/2027
    BRAF • HLA-A
    |
    BRAF mutation • BRAF V600 • HLA-A*02
    |
    Opdualag (nivolumab/relatlimab-rmbw) • brenetafusp (IMC-F106C) • relatlimab (BMS-986016)
    Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors (NCT04262466)
    Phase 1/2
    Immunocore Ltd
    Recruiting
    Last update posted :
    04/02/2024
    Initiation :
    02/25/2020
    Primary completion :
    06/01/2026
    Completion :
    06/01/2026
    HLA-A • PRAME
    |
    HLA-A*02
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • Kimmtrak (tebentafusp-tebn) • brenetafusp (IMC-F106C)